Browse the evidence

Obesity is defined as a BMI of more than 30 kg/m2 and is a prevalent chronic disease.

Healthcare practitioners should recognize obesity as a significant health challenge.

The incidence of obesity has nearly trebled since 1975.

Public health initiatives must address the rising rates of obesity.

The comparative bioavailability of semaglutide following oral administration (3 mg) relative to subcutaneous administration (0.25 mg) is 0.66%.

Practitioners should note the lower bioavailability of oral semaglutide compared to subcutaneous administration.

The pharmacokinetics of semaglutide was characterized following the administration of low subcutaneous and oral doses.

Understanding the pharmacokinetics can inform dosing strategies for semaglutide.

The study drug was well tolerated, and no serious adverse events were reported.

Practitioners can consider semaglutide safe for use in healthy individuals based on this study.

There were no reports of pharmacotherapies for weight management in the studies reviewed.

Practitioners should be aware that pharmacotherapy options are not currently reported for this population.

Research is being pursued to investigate glucose-lowering agents for their anti-inflammatory, neuroprotective, and lipotoxic reduction effects.

Future research may expand the therapeutic applications of these medications.

Obstacles in integrating injectables into existing regimens include restricted access to information and insufficient training.

Training and access to information are crucial for effective diabetes management.

SGLT-2 inhibitors lower blood sugar independently of insulin, reduce heart failure risk, slow kidney disease progression, and possess senolytic properties.

SGLT-2 inhibitors may be beneficial for patients with diabetes and related complications.

Molecular engineering strategies have advanced biologic therapies for diabetes by optimizing therapeutic stability, pharmacokinetics, and delivery.

Practitioners can leverage molecular engineering to enhance diabetes therapies.

Structural modifications such as amino acid substitutions and PEGylation enhance stability and extend half-life of diabetes therapeutics.

Incorporating these modifications can improve the efficacy of diabetes treatments.

Tirzepatide can cause acute hepatocellular liver injury in patients.

Clinicians should monitor liver function in patients using tirzepatide.

Hepatotoxicity is not a widely recognized complication of tirzepatide.

Awareness of potential liver injury should be increased among healthcare providers prescribing tirzepatide.

Symptoms of liver injury resolved and liver enzymes normalized within 3 weeks of presentation.

Patients may recover from tirzepatide-induced liver injury with appropriate monitoring.

Diabetes Mellitus (DM) is caused by interactions between multiple factors and triggers.

Understanding the multifactorial nature of DM can guide prevention and treatment strategies.

Numerous medications for diabetics have been developed to help alleviate the symptoms of hyperglycemia.

Practitioners can utilize a variety of medications to manage hyperglycemia in diabetic patients.

Some factors and mechanisms involved in DM development are controversial and have contradicting experimental results.

Awareness of controversial factors can inform research directions and clinical approaches.

The previous version of the guideline did not include a literature review for obesity surgery due to limited resources, and it references an existing guideline for obesity surgery.

Clinicians should be aware of the referenced guidelines for obesity surgery when making treatment decisions.

iWAT injection of MPDA@TZP improved leptin resistance, beiging, lipid metabolism, mitochondrial activity, and branched-chain amino acid (BCAA) catabolism in iWAT.

Understanding these metabolic improvements can guide targeted therapies for obesity.

Leptin receptor deficiency in db/db mice abolished the weight reduction effect of MPDA@TZP via iWAT local injection compared to that in DIO mice.

Leptin receptor status should be considered when evaluating treatment efficacy for obesity.

More work is needed to understand the mechanisms and full potential of antiobesity medicines in cancer.

Ongoing research is essential to fully understand the implications of antiobesity medications on cancer.

HMB supplementation failed to demonstrate significant benefits for muscle strength (SMD = -0.22, 95% CI: -0.57, 0.12) or mass outcomes (MD = 0.05, 95% CI: -0.33, 0.44).

HMB supplementation may not be effective for improving muscle strength or mass in older adults.

The present study did not find an association between resistance training (RT) and all-cause mortality.

Resistance training may not significantly impact overall mortality risk.

Neither meeting the guidelines nor monthly RT volume was associated with all-cause mortality in adjusted models.

Adherence to resistance training guidelines or volume does not appear to influence mortality risk.